Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
NCT07287137
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2026 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- COVID -19
- COVID - 19
- COVID 19
- Influenza
- Respiratory Virus
- Respiratory Viruses
- Respiratory Virus Infection
- Respiratory Virus Infections
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 79 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Last updated on ClinicalTrials.gov
- October 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Walter Reed National Military Medical Center · Bethesda, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.